Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Pregabalin As Adjunctive Therapy in Children 4 -16 Years of Age With Partial Onset Seizures

Trial Profile

A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Pregabalin As Adjunctive Therapy in Children 4 -16 Years of Age With Partial Onset Seizures

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Acronyms PERIWINKLE
  • Sponsors Pfizer

Most Recent Events

  • 05 Dec 2020 Results of pooled analysis of pregabalin concentration and efficacy data (from 10 studies) assessing population pharmacokinetic and exposure-response analyses, to compare pregabalin exposure and E-R relationships in pediatric and adult patients with FOS, published in the Clinical Pharmacology and Therapeutics
  • 05 Dec 2017 Results presented at the 71st Annual Meeting of the American Epilepsy Society
  • 01 Dec 2016 Primary endpoint has not been met. (Log transformed (loge) 28 day seizure rate for all partial onset seizures collected during the 12 week double-blind treatment phase, reported as percent reduction in seizures relative to placebo. [ Time Frame: 12 weeks ] For Dose 2.5 mg/kg/day), as reported in a Pfizer media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top